home / stock / huge / huge news

HUGE News and Press, FSD Pharma Inc. From 04/17/23

Stock Information
Company Name: FSD Pharma Inc.
Stock Symbol: HUGE
Market: NASDAQ
Website: fsdpharma.com
Menu
HUGE HUGE Quote HUGE Short HUGE News HUGE Articles HUGE Message Board
Get HUGE Alerts

News, Short Squeeze, Breakout and More Instantly...
HUGE - InvestorNewsBreaks - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Completes Critical Step in Advancing Lucid-MS Pipeline

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders. The company today announced completion of the fi...
HUGE - FSD Pharma Achieves Milestone in Completion of Dosing of Sentinel Subjects in First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“ FSD Pharma ” or the “ Company ”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory...

HUGE - FSD Pharma plans to spin out subsidiary

2023-04-12 09:03:12 ET Canadian biotech FSD Pharma ( NASDAQ: HUGE ) announced Wednesday that it intends to spin out a yet-to-be-formed wholly-owned subsidiary to focus on the development of its core assets and maximize shareholder value. Following the transaction, expected to ...

HUGE - FSD Pharma Announces Plan to Spin-Out Subsidiary as Distribution to Shareholders; Shareholder Meeting Scheduled for June 29, 2023

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“ FSD Pharma ” or the “ Company ”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory...
HUGE - FSD Pharma GAAP EPS of -$0.69

2023-04-03 00:58:15 ET FSD Pharma press release ( NASDAQ: HUGE ): FY GAAP EPS of -$0.69. Cash and cash equivalents of $16.98M. For further details see: FSD Pharma GAAP EPS of -$0.69

HUGE - FSD Pharma Announces Filing of Year-End 2022 Results

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“ FSD Pharma ” or the “ Company ”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory...

HUGE - InvestorNewsBreaks - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Strategic Board Appointment of Gerry David

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, today announced the appointment of Gerry David to ...
HUGE - FSD Pharma Adds Former Celsius Holdings CEO Gerry David to Board of Advisors

Previously Headed Successful Global Expansion Resulting in Dramatic Increase in Sales and 35-Fold Increase in Shareholder Value for Drink Business FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“ FSD Pharma ” or the “ Company ”), a biopharm...

HUGE - FSD Pharma gets ethics panel nod in Australia for phase 1 trial of depression drug

2023-03-22 11:39:43 ET FSD Pharma ( NASDAQ: HUGE ) said it received a certificate of approval from The Alfred Ethics Committee in Australia to proceed with a phase 1 trial of Lucid-201 (Lucid-Psych)  to treat Major Depressive Disorder (MDD). Lucid-Psych is being ...

HUGE - InvestorNewsBreaks - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Subsidiary Receives Official Approval to Move Forward with Phase 1 Clinical Trial

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, announced that its Australian entity, FSD Pharma A...
Previous 10 Next 10